Positive News Sentiment NASDAQ:ITCI Intra-Cellular Therapies Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Intra-Cellular Therapies, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $55.17 -1.91 (-3.35%) (As of 07/1/2022 05:43 PM ET) Add Compare Share Today's Range$53.13▼$57.1250-Day Range$43.00▼$59.4152-Week Range$28.40▼$66.00Volume896,500 shsAverage Volume1.04 million shsMarket Capitalization$5.20 billionP/E RatioN/ADividend YieldN/APrice Target$62.25 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability Intra-Cellular Therapies Stock Forecast (MarketRank)Analyst RatingModerate Buy2.88 Rating ScoreUpside/Downside12.8% Upside$62.25 Price TargetShort InterestBearish8.13% of Float Sold ShortDividend StrengthN/ASustainability-1.38Upright™ Environmental ScoreNews SentimentN/AInsider TradingSelling Shares$6.11 M Sold Last QuarterProj. Earnings GrowthGrowingFrom ($2.95) to ($1.28) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as 30% analysis score, 20% valuation score, 10% short interest score, 10% dividend score, 10% sustainability score, 10% news and social score, and 10% insider trading score.2.21 out of 5 starsMedical Sector623rd out of 1,429 stocksPharmaceutical Preparations Industry284th out of 682 stocks 2.4 Analyst's Opinion Consensus RatingIntra-Cellular Therapies has received a consensus rating of Moderate Buy. The company's average rating score is 2.88, and is based on 7 buy ratings, 1 hold rating, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $62.25, Intra-Cellular Therapies has a forecasted upside of 12.8% from its current price of $55.17.Amount of Analyst CoverageIntra-Cellular Therapies has only been the subject of 3 research reports in the past 90 days. Previous Next 1.0 Short Interest Percentage of Shares Shorted8.13% of the float of Intra-Cellular Therapies has been sold short.Short Interest Ratio / Days to CoverIntra-Cellular Therapies has a short interest ratio ("days to cover") of 4.1.Change versus previous monthShort interest in Intra-Cellular Therapies has recently increased by 15.06%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldIntra-Cellular Therapies does not currently pay a dividend.Dividend GrowthIntra-Cellular Therapies does not have a long track record of dividend growth. Previous Next 3.7 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreIntra-Cellular Therapies has received a 67.21% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Antipsychotics", "Clinical research services for psychotic disorders", and "Clinical research services for mood disorders" products. See details.Environmental SustainabilityThe Environmental Impact score for Intra-Cellular Therapies is -1.38. Previous Next 3.3 News and Social Media Coverage News SentimentIntra-Cellular Therapies has a news sentiment score of 1.89. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.76 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for Intra-Cellular Therapies this week, compared to 1 article on an average week.Search Interest2 people have searched for ITCI on MarketBeat in the last 30 days. MarketBeat FollowsOnly 3 people have added Intra-Cellular Therapies to their MarketBeat watchlist in the last 30 days. This is a decrease of -40% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Intra-Cellular Therapies insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $6,108,221.00 in company stock.Percentage Held by Insiders13.20% of the stock of Intra-Cellular Therapies is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions73.40% of the stock of Intra-Cellular Therapies is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Intra-Cellular Therapies are expected to grow in the coming year, from ($2.95) to ($1.28) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Intra-Cellular Therapies is -15.20, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Intra-Cellular Therapies is -15.20, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioIntra-Cellular Therapies has a P/B Ratio of 10.75. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive ITCI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Intra-Cellular Therapies and its competitors with MarketBeat's FREE daily newsletter. Email Address About Intra-Cellular Therapies (NASDAQ:ITCI)Intra-Cellular Therapies, Inc., a biopharmaceutical company, develops novel drugs for the treatment of neuropsychiatric and neurologic diseases by targeting intracellular signaling mechanisms within the central nervous system in the United States. The company offers CAPLYTA for the treatment of schizophrenia in adults. It is also involved in developing lumateperone, which is in Phase III clinical trial for the treatment of bipolar depression, as well as to treat autism spectrum disorder; and in additional neuropsychiatric indications, such as sleep disorders associated with neuropsychiatric and neurological disorders. In addition, the company is developing Lenrispodun (ITI-214) for the treatment of Parkinson's disease and heart failure; ITI-1284-ODT-SL for the treatment of neuropsychiatric disorders and behavioral disturbances in dementia; and ITI-333 for substance use disorders, pain, and psychiatric comorbidities, including depression and anxiety. Intra-Cellular Therapies, Inc. was founded in 2002 and is headquartered in New York, New York.Read More ITCI Stock News HeadlinesJune 16, 2022 | apnews.comINVESTIGATION ALERT: The Schall Law Firm Encourages Investors in Intra-Cellular Therapies, Inc. with Losses to Contact the FirmJune 15, 2022 | americanbankingnews.comUBS Group Initiates Coverage on Intra-Cellular Therapies (NASDAQ:ITCI)June 13, 2022 | finance.yahoo.comIntra-Cellular Therapies Highlights Lumateperone Bipolar Depression Data Presentations at the 2022 International Society for Bipolar Disorders (ISBD) ExperienceJune 9, 2022 | americanbankingnews.comResearch Analysts Set Expectations for Intra-Cellular Therapies, Inc.'s FY2023 Earnings (NASDAQ:ITCI)May 29, 2022 | finance.yahoo.comThose who invested in Intra-Cellular Therapies (NASDAQ:ITCI) five years ago are up 457%May 11, 2022 | finance.yahoo.comIntra-Cellular Therapies Stock Clears Technical Benchmark, Hitting 90-Plus RS RatingMay 10, 2022 | fool.comWhy Intra-Cellular Therapies Trounced the S&P 500 TodayMay 10, 2022 | seekingalpha.comIntra-Cellular Therapies, Inc. (ITCI) CEO Sharon Mates on Q1 2022 Results - Earnings Call TranscriptMay 10, 2022 | seekingalpha.comIntra-Cellular rises 18% as robust demand for bipolar depression drug drives Q1 beatMay 10, 2022 | finance.yahoo.comIntra-Cellular Therapies Reports First Quarter 2022 Financial Results and Provides Corporate UpdateMay 10, 2022 | seekingalpha.comIntra-Cellular Therapies GAAP EPS of -$0.78 beats by $0.15, revenue of $35M beats by $1.48MMay 9, 2022 | finance.yahoo.comAtyr Pharma (LIFE) Reports Q1 Loss, Misses Revenue EstimatesMay 9, 2022 | seekingalpha.comIntra-Cellular Therapies Q1 2022 Earnings PreviewSee More Headlines Industry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:ITCI CUSIPN/A CIK1567514 Webwww.intracellulartherapies.com Phone(464) 440-9333Fax646-440-9334Employees512Year FoundedN/ACompany Calendar Last Earnings5/10/2022Today7/01/2022Next Earnings (Estimated)8/08/2022Fiscal Year End12/31/2022Price Target and Rating Average Stock Price Forecast$62.25 High Stock Price Forecast$75.00 Low Stock Price Forecast$40.00 Forecasted Upside/Downside+12.8%Consensus RatingModerate Buy Rating Score (0-4)2.875 Research Coverage8 Analysts Profitability EPS (Most Recent Fiscal Year)($3.630010) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-284.13 million Net Margins-294.89% Pretax Margin-294.89% Return on Equity-53.93% Return on Assets-47.77% Debt Debt-to-Equity RatioN/A Current Ratio14.36 Quick Ratio14.23 Sales & Book Value Annual Sales$83.80 million Price / Sales62.10 Cash FlowN/A Price / Cash FlowN/A Book Value$5.13 per share Price / Book10.75Miscellaneous Outstanding Shares94,324,000Free Float81,873,000Market Cap$5.20 billion OptionableOptionable Beta1.28 Intra-Cellular Therapies Frequently Asked Questions Should I buy or sell Intra-Cellular Therapies stock right now? 8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Intra-Cellular Therapies in the last twelve months. There are currently 1 hold rating and 7 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" Intra-Cellular Therapies stock. View analyst ratings for Intra-Cellular Therapies or view top-rated stocks. What is Intra-Cellular Therapies' stock price forecast for 2022? 8 equities research analysts have issued 1 year price targets for Intra-Cellular Therapies' stock. Their ITCI stock forecasts range from $40.00 to $75.00. On average, they expect Intra-Cellular Therapies' stock price to reach $62.25 in the next twelve months. This suggests a possible upside of 12.8% from the stock's current price. View analysts' price targets for Intra-Cellular Therapies or view top-rated stocks among Wall Street analysts. How has Intra-Cellular Therapies' stock performed in 2022? Intra-Cellular Therapies' stock was trading at $52.34 at the beginning of 2022. Since then, ITCI shares have increased by 5.4% and is now trading at $55.17. View the best growth stocks for 2022 here. When is Intra-Cellular Therapies' next earnings date? Intra-Cellular Therapies is scheduled to release its next quarterly earnings announcement on Monday, August 8th 2022. View our earnings forecast for Intra-Cellular Therapies. How were Intra-Cellular Therapies' earnings last quarter? Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) issued its earnings results on Tuesday, May, 10th. The biopharmaceutical company reported ($0.78) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.93) by $0.15. The biopharmaceutical company earned $35 million during the quarter, compared to analysts' expectations of $33.52 million. Intra-Cellular Therapies had a negative trailing twelve-month return on equity of 53.93% and a negative net margin of 294.89%. The firm's revenue was up 120.1% on a year-over-year basis. During the same period in the previous year, the business earned ($0.65) EPS. View Intra-Cellular Therapies' earnings history. Who are Intra-Cellular Therapies' key executives? Intra-Cellular Therapies' management team includes the following people: Dr. Sharon Mates Ph.D., Co-Founder, Chairman, CEO & Pres (Age 69, Pay $2.25M)Mr. Lawrence J. Hineline CPA, CPA, Sr. VP of Fin., CFO, Treasurer & Assistant Sec. (Age 66, Pay $791.01k) (LinkedIn Profile)Mr. Michael I. Halstead J.D., Exec. VP, Gen. Counsel & Sec. (Age 49, Pay $1.08M)Dr. Suresh K. Durgam M.D., Exec. VP & Chief Medical Officer (Age 53, Pay $1.03M) (LinkedIn Profile)Mr. Mark Neumann, EVP & Chief Commercial Officer (Age 59, Pay $1.01M) (LinkedIn Profile)Dr. Robert E. Davis Ph.D., Sr. VP & Chief Scientific Officer (Age 71)Mr. Juan Fernando Sanchez, VP of Corp. Communications & Investor Relations (Age 51)Ms. Karen Patruno Sheehy Esq., Sr. VP & Chief Compliance Officer (Age 60)Dr. Michael Olchaskey, Sr. VP & Head of Regulatory AffairsMr. John A. Bardi, Sr. VP of Market Access, Policy & Gov. Affairs Who are some of Intra-Cellular Therapies' key competitors? Some companies that are related to Intra-Cellular Therapies include Catalent (CTLT), Horizon Therapeutics Public (HZNP), Alnylam Pharmaceuticals (ALNY), BeiGene (BGNE), Shiseido (SSDOY), UCB (UCBJF), BioMarin Pharmaceutical (BMRN), Viatris (VTRS), Ono Pharmaceutical (OPHLF), United Therapeutics (UTHR), Biohaven Pharmaceutical (BHVN), Jazz Pharmaceuticals (JAZZ), Elanco Animal Health (ELAN), Dr. Reddy's Laboratories (RDY) and Teva Pharmaceutical Industries (TEVA). View all of ITCI's competitors. What other stocks do shareholders of Intra-Cellular Therapies own? Based on aggregate information from My MarketBeat watchlists, some companies that other Intra-Cellular Therapies investors own include Sorrento Therapeutics (SRNE), Amarin (AMRN), Gilead Sciences (GILD), CRISPR Therapeutics (CRSP), Synergy Pharmaceuticals (SGYP), Myovant Sciences (MYOV), Novavax (NVAX), Pfizer (PFE), AbbVie (ABBV) and Clovis Oncology (CLVS). What is Intra-Cellular Therapies' stock symbol? Intra-Cellular Therapies trades on the NASDAQ under the ticker symbol "ITCI." How do I buy shares of Intra-Cellular Therapies? Shares of ITCI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Intra-Cellular Therapies' stock price today? One share of ITCI stock can currently be purchased for approximately $55.17. How much money does Intra-Cellular Therapies make? Intra-Cellular Therapies (NASDAQ:ITCI) has a market capitalization of $5.20 billion and generates $83.80 million in revenue each year. The biopharmaceutical company earns $-284.13 million in net income (profit) each year or ($3.630010) on an earnings per share basis. How many employees does Intra-Cellular Therapies have? Intra-Cellular Therapies employs 512 workers across the globe. How can I contact Intra-Cellular Therapies? Intra-Cellular Therapies' mailing address is 430 EAST 29TH STREET, NEW YORK NY, 10016. The official website for Intra-Cellular Therapies is www.intracellulartherapies.com. The biopharmaceutical company can be reached via phone at (464) 440-9333, via email at [email protected], or via fax at 646-440-9334. This page (NASDAQ:ITCI) was last updated on 7/2/2022 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply. MarketBeat Resources Premium Research Tools MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools. Discover All Access Market Data and Calendars Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free. View Market Data Investing Education and Resources Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more. Financial Terms Details Here
